Printer Friendly

BIOGENEX OPENS SUBSIDIARIES IN GERMANY AND JAPAN

 BIOGENEX OPENS SUBSIDIARIES IN GERMANY AND JAPAN
 SAN RAMON, Calif., Jan. 29 /PRNewswire/ -- BioGenex, the


biotechnology company headquartered in San Ramon, has announced the opening of its first foreign subsidiaries: BioGenex Laboratories GmbH in Munich, Germany, and BioGenex KK in Tokyo. Manufacturer of products for tumor and infectious disease diagnosis, fertility aids, and specialized chemicals for molecular biology research, BioGenex has established a worldwide network of distributors serving over 50 nations. According to Dr. Kris Kalra, BioGenex president and CEO, the opening of the two new subsidiaries is expected to "improve the speed and quality of service to foreign customers and permit rapid expansion to the Japanese and European marketplaces." BioGenex Laboratories GmbH in Munich
 Strategically located near the world's most modern airport (the nation's largest) at Munich, BioGenex Laboratories GmbH will act as a central warehouse serving BioGenex distributors throughout Europe, Africa and the Middle East. In addition, the German subsidiary will serve as a base for marketing efforts in these regions and will provide technical support to foreign customers for the entire BioGenex product line. The "key advantage to be here for BioGenex," said Dr. Silvano Cometta, subsidiary director at BioGenex Laboratories GmbH, "is to be close to the (foreign) customer." The success achieved by BioGenex in the highly competitive health care market, according to Dr. Cometta, is due in part to its commitment to provide customer training via educational workshops and readily accessible telephone support. These activities can now be extended to the European market.
 Germany is a prime location for the BioGenex subsidiary because of its growing economy, its sophisticated health care infrastructure, its central location in Europe, and its status as a member of the European Community (EC). The latter fact will facilitate the rapid shipment of products in Europe, since there is free flow of goods across the borders of EC member nations. The German subsidiary is also expected to serve as an important channel for regional business development, in particular, for establishing new foreign distributors and for supporting current ones. BioGenex Laboratories GmbH is located at Hanns-Braun-Strasse 52, D-8056 Neufahrn, Munich, Germany; telephone 49-8165-4040; telefax 49-8165-4080. BioGenex KK in Tokyo
 The establishment of BioGenex KK, the new BioGenex subsidiary in Tokyo will permit the rapid entry of BioGenex products into the second largest healthcare market in the world. The Japanese subsidiary will serve as a center for the importation, warehousing and marketing of all BioGenex products in Japan. In addition, BioGenex KK will sell directly to the Japanese research market and provide complete technical support to its Japanese customers.
 According to Katsuko Yamada, president of BioGenex KK, products must first be approved for sale to clinical laboratories by the government Ministry of Health and Welfare (analogous to FDA approval in the United States). Yamada said that a distribution agreement with an established medical supply company, as currently pursued by the new subsidiary, will expedite the entry of BioGenex products into the Japanese clinical market. In addition, Yamada believes that the establishment of the Japanese subsidiary will enable BioGenex to pursue collaborative arrangements for research and development in Japan. BioGenex KK is located at Takanawa Daiichi Heights 201, 2-12-51 Takanawa, Tokyo, Japan; telephone 81-3-3448-0875; telefax 81-3-3448-0889.
 -0- 1/29/92
 /CONTACT: Jeffrey Prince of BioGenex, 510-275-0550/ CO: BioGenex ST: California IN: MTC SU:


RM -- SF002 -- 4758 01/29/92 13:00 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 29, 1992
Words:558
Previous Article:PRESIDENT'S ADDRESS OFFERS RENEWED HOPE TO SMALL BUSINESSES, NSBU SAYS
Next Article:'THE MAMBO KINGS' TO KICK OFF NINTH MIAMI FILM FESTIVAL
Topics:


Related Articles
BIOGENEX TAKES ACTION AGAINST BIOTEK SOLUTIONS FOR ALLEGED INFRINGEMENT OF ANTIGEN RETRIEVAL PATENT
BioGenex Awarded Punitive Damages in Patent Suit Against BioTek Subsidiary of Ventana
BioGenex Awarded U.S. Patent on the Synthesis of Branched Oligomers For Nucleic Acid Labeling and Amplification.
BioGenex Awarded Second U.S. Patent on OptiMax(R) PLUS, World's Only Consolidated Staining System.
New 'Special Stains' Kits Add Impetus to BioGenex OptiMax(R) PLUS Consolidated Staining System.
BioGenex Institutes Restructuring of Its Organizational Teams.
BioGenex, Inc. Introduces an EZ Retrieval System - a New Paradigm in Antigen Retrieval; Together with the i6000(TM) and iVision(TM) Systems, this...
BioGenex Marketing Gets a Face-Lift; Valerie Goodwin Joins as Director of Marketing.
BioGenex Obtains Favorable Patent Ruling Against Ventana Medical Systems.
Japanese Global Medical Technology Company Opens Office in Switzerland.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters